Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target

H.C Wainwright&CO is initiating coverage of Cybin Inc. with a Buy rating and $8/share price target. Cybin develops alternative formulations and versions of existing psychedelic drugs.